Table 1.
Study Population Characteristics
| Age (yrs) | 58.6 ± 18 |
| Gender (M/F) | 13/1 |
| BMI (g/m2) | 23.8 ± 2.6 |
| Diabetes (Y/N) | 5/9 |
| Known CAD (Y/N) | 5/9 |
| Aetiology of ESRF (DM/HTN/Other) | 5/3/6 |
| ACEi/ARB (Y/N) | 5/9 |
| Calcium channel blocker (Y/N) | 10/4 |
| Beta blocker (Y/N) | 10/4 |
| Alpha blocker (Y/N) | 2/12 |
| Diuretic (Y/N) | 6/8 |
| Use of ESA (Y/N) | 10/4 |
| Time on dialysis (months) | 9 (4–172) |
| Time receiving HD (months) | 6 (1–172) |
| Previous transplant (Y/N) | 4/10 |
| Current HD access (CVC/AVF) | 12/2 |
| Hemoglobin (g/L) | 107 ± 13 |
| Haematocrit (L/L) | 0.324 ± 0.04 |
| Sodium (mmol/L) | 136 ± 3.9 |
| Albumin (g/L) | 38.5 ± 6.2 |
| Bilirubin (μmol/L) | 4.19 ± 1.2 |
M male, F female, Y yes, N no, CAD coronary artery disease, ESRF end-stage renal failure, HTN hypertension, DM diabetes, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ESA erythopoeisis-stimulating agent, CVC central venous catheter, AVF arteriovenous fistula. All blood results represent pre-dialysis values